PharmaShots Weekly Snapshots (October 04 – 08, 2021)

 PharmaShots Weekly Snapshots (October 04 – 08, 2021)

PharmaShots Weekly Snapshots (October 04 – 08, 2021)

AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Published: Oct 8, 2021 | Tags: AbbVie, Rinvoq, upadacitinib, Health Canada, Approval, Atopic Dermatitis

Takeda Receives the US FDA Advisory Committee’s Recommendation for TAK-620 (maribavir) to Treat CMV Infection in Post-Transplant Recipients

Published: Oct 8, 2021 | Tags: Takeda, US, FDA, Advisory Committee, Maribavir, TAK-620, CMV Infection

Allogene Reports the US FDA’s Clinical Hold on ALPHA2 Study of ALLO-501A to Treat Large B Cell Lymphoma

Published: Oct 8, 2021 | Tags: Allogene, US, FDA, Clinical Hold, ALPHA2 Study, ALLO-501A, Large B Cell Lymphoma

Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer

Published: Oct 8, 2021 | Tags: Sanofi, Mirati, Adagrasib, SAR442720, RMC-4630, P-I/II, Study, KRAS G12C-Mutated Lung Cancer

Schrödinger Signs a Two-Year Research Collaboration with MD Anderson to Advance its WEE1 Program

Published: Oct 8, 2021 | Tags: MD Anderson, Schrödinger, WEE1 Program

AbbVie’s Rinvoq (upadacitinib) Met Primary and Secondary Endpoints in P-III SELECT-AXIS 2 Clinical Trial for Non-Radiographic Axial Spondyloarthritis

Published: Oct 8, 2021 | Tags: AbbVie, Rinvoq, upadacitinib, P-III, SELECT-AXIS 2 Clinical Trial, Non-Radiographic Axial Spondyloarthritis

BMS’ Deucravacitinib Fails to Meet its Primary and Secondary Endpoints in P-II LATTICE-UC Study for the Treatment of Moderate to Severe Ulcerative Colitis

Published: Oct 7, 2021 | Tags: BMS, Deucravacitinib, P-II, LATTICE-UC Study, Ulcerative Colitis

Amgen Signs a R&D Collaboration with Neumora to Advance Novel Precision Therapies for Neuropsychiatric and Neurodegenerative Diseases

Published: Oct 7, 2021 | Tags: Amgen, R&D Collaboration, Neumora, Novel Precision Therapies, Neuropsychiatric, Neurodegenerative Diseases

Denali Presented Results of DNL343 and SAR443820 in P-I Clinical Studies for the Treatment of Amyotrophic Lateral Sclerosis at NEALS 2021

Published: Oct 7, 2021 | Tags: Denali, DNL343, SAR443820, P-I, Clinical Study, Amyotrophic Lateral Sclerosis, NEALS 2021

PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease

Published: Oct 7, 2021 | Tags: PharmaTher, P-II, KET-LID Study, Ketamine, Levodopa-Induced Dyskinesia, Parkinson’s Disease

Sanofi Reports Interim Results of Fluzone High-Dose Quadrivalent Vaccine + COVID-19 mRNA Booster Dose in First Descriptive Study for COVID-19

Published: Oct 7, 2021 | Tags: Sanofi, Fluzone High-Dose Quadrivalent Vaccine, COVID-19 mRNA Booster Dose, Descriptive Study, COVID-19

Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases

Published: Oct 7, 2021 | Tags: Pfizer, Voyager, Gene Therapies, Neurologic, Cardiovascular Diseases

Boston to Acquire Baylis for ~$1.75B

Published: Oct 6, 2021 | Tags: Boston, Acquire, ~$1.75B, Electrophysiology, Structural Heart Product Portfolios

Kaleido Reports Results of KB295 in Clinical and Preclinical Studies for the Treatment of Mild-to-Moderate Ulcerative Colitis

Published: Oct 6, 2021 | Tags: Kaleido, Clinical, KB295, Preclinical Data, Ulcerative Colitis

Novartis’s Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease

Published: Oct 6, 2021 | Tags: Novartis, Adakveo, crizanlizumab, NICE, Recommendation, Sickle Cell Disease

Sage and Biogen Present Results of Zuranolone in LANDSCAPE and NEST Clinical Development Programs for the Treatment of MDD and PPD at ECNP 2021

Published: Oct 6, 2021 | Tags: Sage, Biogen, Zuranolone, LANDSCAPE, NEST Clinical Development Programs, MDD, PPD, ECNP 2021

Johnson & Johnson Reports EUA Submission to the US FDA for Supporting the Booster of its Single Shot COVID-19 Vaccine Candidate

Published: Oct 6, 2021 | Tags: Johnson & Johnson, EUA, US, FDA, Single Shot, COVID-19 Vaccine Candidate

Inotiv to Acquire Plato BioPharma for ~$15.0M

Published: Oct 6, 2021 | Tags: Inotiv, Acquire, Plato BioPharma, ~$15.0M

Guardant Health Initiates ORACLE Study of Guardant Reveal Blood Test for the Treatment of Early-Stage Cancers

Published: Oct 5, 2021 | Tags: Guardant Health, ORACLE Study, Guardant Reveal Blood Test, Early-Stage Cancers

Xenon’s XEN1101 Meets its Primary Efficacy Endpoint in P-IIb X-TOLE Clinical Trial for the Treatment of Focal Epilepsy

Published: Oct 5, 2021 | Tags: Xenon, XEN1101, P-IIb, X-TOLE Clinical Trial, Focal Epilepsy

Coherus Report Results of CHS-201 (biosimilar, ranibizumab) in COLUMBUS-AMD Clinical Trial for the Treatment of nAMD

Published: Oct 5, 2021 | Tags: Coherus, CHS-201, biosimilar, ranibizumab, COLUMBUS-AMD Clinical Trial, nAMD

AstraZeneca Seeks the US FDA’s EUA for AZD7442 to Treat COVID-19

Published: Oct 5, 2021 | Tags: AstraZeneca, US, FDA, EUA, ZD7442, COVID-19, US

Polpharma Biologics Reports the US FDA’s Acceptance of BQ201’s (biosimilar, ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration

Published: Oct 5, 2021 | Tags: Polpharma Biologics, US, FDA, Acceptance, BQ201, biosimilar, ranibizumab, BLA, Wet Age-Related Macular Degeneration

Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders

Published: Oct 5, 2021 | Tags: Takeda, Selecta, Gene Therapies, Lysosomal Storage Disorders

Xencor Enter into an Exclusive WW License Agreement with Janssen to Develop and Commercialize Plamotamab and Xmab CD28 Bispecific Antibody for B-Cell Malignancies

Published: Oct 4, 2021 | Tags: Xencor, Janssen, Plamotamab, Xmab B-Cell, B-Cell Malignancies

ViiV Healthcare Submits Regulatory Applications to the US FDA for a New Dispersible Tablet Formulation of Abacavir/Dolutegravir/Lamivudine to Treat HIV in Children

Published: Oct 4, 2021 | Tags: ViiV Healthcare, US, FDA, Triumeq, abacavir, dolutegravir, lamivudine, Approval, HIV

Janssen Presented Results of RSV Vaccine in P-IIb CYPRESS Study for Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus at IDWeek 2021

Published: Oct 4, 2021 | Tags: Janssen, RSV Vaccine, P-IIb, CYPRESS Study, Lower Respiratory Tract Disease, Respiratory Syncytial Virus, IDWeek 2021

Formycon and Bioeq Report the US FDA’s Acceptance of BLA for FYB201 (biosimilar, ranibizumab)

Published: Oct 4, 2021 | Tags: Formycon, Bioeq, US, FDA, Acceptance, BLA, FYB201, biosimilar, ranibizumab

Merck KGaA and GSK Terminate their ~$4.2B Collaboration Due to Clinical Failures

Published: Oct 4, 2021 | Tags: Merck KGaA, GSK, ~$4.2B,

Kite’s Tecartus Receives the US FDA’s Approval as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Published: Oct 4, 2021 | Tags: Kite, Tecartus, US, FDA, Approval, Car T, Refractory B-cell Acute Lymphoblastic Leukemia

Related Post: PharmaShots Weekly Snapshots (September 27 – October 01, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post